A New Day Begins With Spravato
FDA Approved
IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT (AD) FOR TREATMENT-RESISTANT DEPRESSION (TRD) IN ADULTS¹
​
The first and only NMDA receptor antagonist approved for TRD in adults
SPRAVATO™ hypothesized mechanism of action
BASELINE PSYCHIATRIC PATIENT CHARACTERISTICS
References:​
1.SPRAVATO™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. March 2019.
2.Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.
Indication:
SPRAVATO™ (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults.​
SPRAVATO™ is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO™ as an anesthetic agent have not been established.
For more information on SPRAVATO treatment, call our mental health clinic at 855.4CHARAK